P. Thomas Bright

Thomas represents publicly traded and privately held companies across a wide range of industries, including retail, financial services, pharmaceutical and life sciences, energy, and real estate. He advises on mergers and acquisitions, other complex commercial transactions, securities offerings, securities regulation and corporate governance.

In his public company practice, he regularly assists clients with federal securities law compliance, periodic reporting requirements, stock exchange compliance, shareholder meetings, and board-level governance and transactional matters. Thomas has also represented public companies in mergers and acquisitions, including take-private transactions.

In his private company practice, Thomas advises private equity funds and their portfolio companies and strategic purchasers and sellers in a variety of merger and acquisition transactions and post-transaction integration matters.

Thomas also maintains an active pro bono practice. He frequently counsels aspiring nonprofit organizations from formation through application for recognition of federal tax exemption as well as with ongoing governance items.

• Advised TXNM Energy, Inc. in its agreement to be acquired by Blackstone Infrastructure at a total enterprise value of $11.5 billion.
• Advised KORE Group Holdings in its agreement to be acquired by Searchlight Capital Partners and Abry Partners in a transaction valued at $726 million.
• Represented a publicly traded real estate investment trust in its establishment of an at-the-market program for selling its common shares.
• Represented a publicly traded specialty pharmaceutical company in its $200 million private investment in public equity (PIPE) transaction.
• Represented a publicly traded specialty pharmaceutical company in its establishment of an at-the-market program for selling its common stock.
• Represented a publicly traded real estate investment trust in its $550 million underwritten public offering of senior notes.
• Represented a UK-based trenchless rehabilitation manufacturer in the sale of its U.S. business.
• Represented a publicly traded owner/operator of franchised businesses in a go-private transaction.
• Represented a private equity portfolio company in the acquisition of drug testing services businesses.
• Represented private equity fund portfolio companies in connection with various day to day business matters, including corporate governance, financing, contract, and executive compensation matters.